MOTS-c
Also known as: Mitochondrial-derived peptide
MOTS-c is a mitochondrial-derived peptide studied for reported effects on metabolism and cellular stress responses. It is a research peptide and is not approved for human use.
- Category
- Longevity / Mitochondrial
- Reported half-life
- Not well established
- Common forms
- Lyophilised powder for reconstitution, Research-grade solution
- Research status
- An active subject of metabolic and ageing research, mostly preclinical; not approved for human use in Australia. Human clinical data are limited.
- Last updated
- 21 June 2026
Claimed effects
The following effects are reported or claimed by users and in early research. They are not established medical facts and many are not supported by large human trials.
- Reported in research to influence metabolic regulation and insulin sensitivity
- Studied for possible effects on exercise and physical performance in animal models
- Reported to interact with cellular energy-sensing pathways such as AMPK
- Reported to be associated with metabolic stress responses
How it is reported to work
MOTS-c is a small peptide encoded within the mitochondrial genome. It is proposed to translocate to the cell nucleus under metabolic stress and to influence energy-sensing pathways such as AMPK, with reported effects on glucose and lipid metabolism. These proposed mechanisms come largely from animal and laboratory studies and are not established in humans.
Background
MOTS-c is a mitochondrial-derived peptide - a small peptide encoded in the DNA of mitochondria rather than the cell nucleus. It is studied as part of research into metabolism and ageing. This page is educational information, not medical advice, and the effects below are reported claims, not established facts.
What the research shows
Most MOTS-c research is preclinical, conducted in cell and animal models studying its proposed role in energy metabolism and exercise responses. These findings are preliminary and have not been confirmed in large human trials.
| Evidence type | Status |
|---|---|
| Cell / animal studies | Present |
| Large human clinical trials | Lacking |
| Australian approval | None |
What people use it for (reported)
Online, people report interest in MOTS-c for metabolism, energy and physical performance. These are anecdotal reports without validated human outcomes. Reported benefits should not be read as proven, and nothing here is encouragement to use it.
Things to be aware of
MOTS-c is not approved for human use in Australia, and its long-term safety in people is not well characterised. Because it is reported to affect metabolic pathways, effects on blood glucose and related systems are uncertain, and grey-market preparations cannot be verified for purity or identity. If you have a metabolic or other health concern, the appropriate step is to consult a qualified healthcare professional. This article does not recommend obtaining or using MOTS-c.
Reported positives & side effects
Compiled from research and community reports. These are reported outcomes, not guarantees or medical advice, individual experiences vary widely.
Reported positives
- Reported by users to be associated with improved energy and reduced fatigue
- Reported in research to influence metabolic regulation and insulin sensitivity
- Reported to be linked with exercise capacity and physical performance in animal models
- Reported to interact with cellular energy-sensing pathways such as AMPK
- Reported to be associated with metabolic stress and ageing-related pathways
Common side effects
- Reported injection-site redness, swelling or irritation
- Reported transient fatigue or lethargy after dosing
- Reported lightheadedness, possibly linked to changes in blood glucose
- Reported mild flushing
Rare / serious side effects
- Reported hypoglycaemia-like symptoms due to reported metabolic effects
- Reported allergic or hypersensitivity reactions to unverified preparations
- Reported infection risk from non-sterile reconstitution and injection
- Unknown long-term effects, as robust human safety data is lacking
Reported misuse & overdose risks
What has been reported to happen with overuse, excessive dosing, or long-term misuse of MOTS-c. Listed so you can make an informed decision, not to suggest any use is safe.
- Reported self-injection of unregulated grey-market powder of unverified purity or identity
- Reported combining with diabetes medication, risking compounded effects on blood glucose
- Reported high-frequency or high-dose use chasing performance or metabolic claims
- Reported sharing or reusing needles when self-administering research material
Reported results timeline
Roughly how long people report it takes to notice effects. A general guide from reports, not a promise, and not advice. Users report gradual changes in energy and exercise tolerance over weeks, with metabolic claims unproven in humans.
First effects
Some report subtle energy changes within the first week or two
Noticeable change
Reported changes in energy or exercise tolerance over the first month
Clear results
Any reported metabolic or performance changes described over several weeks to months
Commonly reported dosing & protocol
Reported figures only, NOT a recommendation or dosing advice. These are numbers people report using, compiled for education so you can make an informed decision. We do not advise anyone to take MOTS-c. Many peptides are not approved for human use in Australia. Speak to a qualified healthcare professional.
| Route | Subcutaneous (SubQ) injection |
|---|---|
| Typical reported dose | Reported at roughly 5–10 mg per administration |
| Frequency | Reported about 2–3 times per week |
| Cycle length | Reported in cycles of several weeks; protocols are not well established |
Reported reconstitution (mg → units)
Example only: a 10 mg vial reconstituted with 2 mL of bacteriostatic water gives 5 mg/mL. A 5 mg dose is about 1 mL (100 units on a U-100 syringe); a 10 mg dose is about 2 mL (200 units).
Work out the units for your vial → CalculatorReported use is commonly described as cycles of several weeks of dosing, sometimes around training periods, then a break. This is reported information about patterns of use, not advice.
Best used with / commonly stacked with
Combinations people report using together. Reported, not recommended, stacking can increase risks.
Safety notes
MOTS-c is not approved for human use in Australia and has limited human safety data. Because it is reported to influence metabolic pathways, potential effects on blood glucose and other systems are not well characterised, and grey-market purity cannot be verified. Anyone with a health concern should consult a qualified healthcare professional rather than self-experiment.